NUVL News - Candlesense

Nuvalent to Present Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC at WCLC 2025 Presidential Symposium

CAMBRIDGE, Mass., Aug. 13, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kina...

What is the expected reaction from institutional investors and analyst coverage after the data is presented? Could the trial outcomes lead to a re‑rating of the company's valuation by analysts? What are the key regulatory or clinical milestones following the ARROS-1 data release?

Clinical trials

10 days ago

Nuvalent Appoints Christy Oliger to Board of Directors

CAMBRIDGE, Mass., June 18, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kina...

Appointments

2 months ago